JP2023529691A5 - - Google Patents
Info
- Publication number
- JP2023529691A5 JP2023529691A5 JP2022575895A JP2022575895A JP2023529691A5 JP 2023529691 A5 JP2023529691 A5 JP 2023529691A5 JP 2022575895 A JP2022575895 A JP 2022575895A JP 2022575895 A JP2022575895 A JP 2022575895A JP 2023529691 A5 JP2023529691 A5 JP 2023529691A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- therapeutically effective
- approximately
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063037469P | 2020-06-10 | 2020-06-10 | |
| US63/037,469 | 2020-06-10 | ||
| US202163195411P | 2021-06-01 | 2021-06-01 | |
| US63/195,411 | 2021-06-01 | ||
| PCT/US2021/036620 WO2021252630A1 (en) | 2020-06-10 | 2021-06-09 | Methods for treating or preventing chronic kidney disease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023529691A JP2023529691A (ja) | 2023-07-11 |
| JP2023529691A5 true JP2023529691A5 (cg-RX-API-DMAC10.html) | 2024-06-10 |
| JP7857235B2 JP7857235B2 (ja) | 2026-05-12 |
Family
ID=78846498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022575895A Active JP7857235B2 (ja) | 2020-06-10 | 2021-06-09 | 慢性腎疾患を処置または防止するための方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230218563A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP4164624A4 (cg-RX-API-DMAC10.html) |
| JP (1) | JP7857235B2 (cg-RX-API-DMAC10.html) |
| KR (1) | KR20230024354A (cg-RX-API-DMAC10.html) |
| AU (1) | AU2021288679A1 (cg-RX-API-DMAC10.html) |
| CA (1) | CA3181902A1 (cg-RX-API-DMAC10.html) |
| IL (1) | IL298833A (cg-RX-API-DMAC10.html) |
| MX (1) | MX2022015678A (cg-RX-API-DMAC10.html) |
| TW (1) | TW202214228A (cg-RX-API-DMAC10.html) |
| WO (1) | WO2021252630A1 (cg-RX-API-DMAC10.html) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113164439A (zh) | 2018-12-06 | 2021-07-23 | 安索治疗公司 | 用于治疗或预防痛风或高尿酸血症的方法 |
| JP2022511800A (ja) | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス,インク. | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| WO2023125667A1 (en) * | 2021-12-30 | 2023-07-06 | Arthrosi Therapeutics, Inc. | Preparation of a compound for the treatment of gout or hyperuricemia |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2291189B1 (en) | 2008-05-22 | 2014-10-01 | AstraZeneca AB | Method for treating hyperuricemia employing an sglt2 inhibitor and composition containing same |
| US9962362B2 (en) * | 2012-03-29 | 2018-05-08 | Children's Hospital Medical Center | Use of small molecule inhibitors targeting EYA tyrosine phosphatase |
| WO2014149789A1 (en) | 2013-03-15 | 2014-09-25 | Janssen Pharmaceutica Nv | Combination of canagliflozin and probenecid for the treament of hyperuricemia |
| AU2017298142B2 (en) * | 2016-07-18 | 2021-11-11 | Arthrosi Therapeutics, Inc. | Compounds, compositions and methods for treating or preventing a symptom associated with gout or hyperuricemia |
| WO2019195118A1 (en) * | 2018-04-03 | 2019-10-10 | Children's Hospital Medical Center | Inhibitors of eya3-protein tyrosine phosphatase in dna damage repair signaling of pulmonary arterial hypertension |
| WO2020070539A1 (en) * | 2018-10-01 | 2020-04-09 | Astrazeneca Ab | Compositions for reducing serum uric acid |
| JP2022511800A (ja) * | 2018-12-06 | 2022-02-01 | アースローシ セラピューティクス,インク. | 痛風または高尿酸血症を処置または予防するための化合物の結晶形態 |
| CA3140412A1 (en) * | 2019-05-14 | 2020-11-19 | Arthrosi Therapeutics, Inc. | Compound for treating gout or hyperuricemia |
-
2021
- 2021-06-09 KR KR1020237000937A patent/KR20230024354A/ko active Pending
- 2021-06-09 WO PCT/US2021/036620 patent/WO2021252630A1/en not_active Ceased
- 2021-06-09 CA CA3181902A patent/CA3181902A1/en active Pending
- 2021-06-09 EP EP21820911.2A patent/EP4164624A4/en active Pending
- 2021-06-09 IL IL298833A patent/IL298833A/en unknown
- 2021-06-09 MX MX2022015678A patent/MX2022015678A/es unknown
- 2021-06-09 TW TW110120962A patent/TW202214228A/zh unknown
- 2021-06-09 AU AU2021288679A patent/AU2021288679A1/en active Pending
- 2021-06-09 JP JP2022575895A patent/JP7857235B2/ja active Active
- 2021-06-09 US US18/001,427 patent/US20230218563A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2086519B1 (en) | Controlled release complex composition comprising angiotensin-ii-receptor blockers and hmg-coa reductase inhibitors | |
| JP2012502015A5 (cg-RX-API-DMAC10.html) | ||
| JP2006523216A5 (cg-RX-API-DMAC10.html) | ||
| WO2008101064A1 (en) | Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and an h2 receptor antagonist | |
| CN103429236A (zh) | 治疗高尿酸血症和与高尿酸血症相关的代谢性病症的方法和组合物 | |
| KR20130097775A (ko) | 테오필린과 페북소스타트의 병용 치료 방법 | |
| Rashid | The efficacy and safety of PDE5 inhibitors | |
| JP2022510303A5 (cg-RX-API-DMAC10.html) | ||
| CN102149377A (zh) | 决奈达隆在制备用于预防中风或短暂性缺血发作的药物中的用途 | |
| JP2020523334A5 (cg-RX-API-DMAC10.html) | ||
| JP2022529208A5 (cg-RX-API-DMAC10.html) | ||
| KR20090037347A (ko) | HMG-CoA 환원효소억제제와 담즙산을 포함하는 C형 간염 치료용 약학조성물 | |
| JP2020522560A5 (cg-RX-API-DMAC10.html) | ||
| JP2004519424A5 (ja) | インシュリン分泌促進剤およびHMG−Co−Aレダクターゼ阻害剤およびACE阻害剤から選択される活性成分を含む組み合わせ | |
| Hiramoto et al. | Evidence-based analysis: postoperative gastric bleeding: etiology and prevention | |
| CN105434417A (zh) | 丹酚酸a在制备抗血管内膜增厚、抗血管成形术后和/或支架内再狭窄药物中的应用 | |
| CN110755432A (zh) | 烟酰胺在制备治疗手足皮肤反应制剂中的应用 | |
| KR20250088666A (ko) | 손 습진의 치료 | |
| JPWO2022071578A5 (cg-RX-API-DMAC10.html) | ||
| IL300406A (en) | Preparations and methods for the treatment or prevention of disease associated with beta corona virus infection | |
| CN101229372A (zh) | 一种治疗高血压的药物组合物 | |
| Rubio et al. | Successful treatment of severe portopulmonary hypertension in a patient with Child C cirrhosis by sildenafil | |
| Caiati et al. | Cardiorenal syndrome triggered by slowly progressive drugs toxicity-induced renal failure along with minimal mitral disease: A case report | |
| Tissières et al. | Aerosolized iloprost as a bridge to lung transplantation in a patient with cystic fibrosis and pulmonary hypertension | |
| S. Hiremath et al. | Recent patents on oral combination drug delivery and formulations |